GLP-1 Pills Are Already Upending the Obesity-Drug Market

For the last year, any discussion of the obesity-drug market has come with an asterisk: Everything will change once pill versions of the popular GLP-1 drugs arrive. Those potentially cheaper alternative to injectables could mean a larger slice of the millions of Americans with obesity will try out the medicine.

Just a month into the arrival of the first pill, a version of Novo Nordisk’s Wegovy, and everything really is changing — and fast. The cost of these highly effective medicines is finally coming down from the stratosphere, and in an ideal world, that will help many more consumers afford to use them consistently.